enGene (ENGN) Competitors $7.95 +0.29 (+3.79%) (As of 10:00 AM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends ENGN vs. NVAX, MESO, VIR, IMTX, LENZ, RLAY, AUTL, CGEM, ADPT, and REPLShould you be buying enGene stock or one of its competitors? The main competitors of enGene include Novavax (NVAX), Mesoblast (MESO), Vir Biotechnology (VIR), Immatics (IMTX), LENZ Therapeutics (LENZ), Relay Therapeutics (RLAY), Autolus Therapeutics (AUTL), Cullinan Therapeutics (CGEM), Adaptive Biotechnologies (ADPT), and Replimune Group (REPL). These companies are all part of the "biological products, except diagnostic" industry. enGene vs. Novavax Mesoblast Vir Biotechnology Immatics LENZ Therapeutics Relay Therapeutics Autolus Therapeutics Cullinan Therapeutics Adaptive Biotechnologies Replimune Group Novavax (NASDAQ:NVAX) and enGene (NASDAQ:ENGN) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, dividends, community ranking, risk, earnings, profitability, media sentiment and valuation. Which has better valuation and earnings, NVAX or ENGN? enGene has lower revenue, but higher earnings than Novavax. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNovavax$983.71M1.27-$545.06M-$2.26-3.46enGeneN/AN/A-$99.92MN/AN/A Which has more volatility & risk, NVAX or ENGN? Novavax has a beta of 2.1, indicating that its share price is 110% more volatile than the S&P 500. Comparatively, enGene has a beta of -0.76, indicating that its share price is 176% less volatile than the S&P 500. Do institutionals and insiders believe in NVAX or ENGN? 53.0% of Novavax shares are held by institutional investors. Comparatively, 64.2% of enGene shares are held by institutional investors. 1.0% of Novavax shares are held by insiders. Comparatively, 13.7% of enGene shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Does the media refer more to NVAX or ENGN? In the previous week, Novavax had 26 more articles in the media than enGene. MarketBeat recorded 33 mentions for Novavax and 7 mentions for enGene. Novavax's average media sentiment score of 0.17 beat enGene's score of 0.17 indicating that Novavax is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novavax 8 Very Positive mention(s) 1 Positive mention(s) 9 Neutral mention(s) 7 Negative mention(s) 2 Very Negative mention(s) Neutral enGene 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts prefer NVAX or ENGN? Novavax presently has a consensus price target of $17.83, indicating a potential upside of 127.76%. enGene has a consensus price target of $31.43, indicating a potential upside of 310.29%. Given enGene's stronger consensus rating and higher possible upside, analysts clearly believe enGene is more favorable than Novavax.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Novavax 1 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.33enGene 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is NVAX or ENGN more profitable? enGene has a net margin of 0.00% compared to Novavax's net margin of -32.18%. Novavax's return on equity of 0.00% beat enGene's return on equity.Company Net Margins Return on Equity Return on Assets Novavax-32.18% N/A -17.05% enGene N/A -66.38%-56.00% Does the MarketBeat Community prefer NVAX or ENGN? Novavax received 838 more outperform votes than enGene when rated by MarketBeat users. However, 100.00% of users gave enGene an outperform vote while only 74.08% of users gave Novavax an outperform vote. CompanyUnderperformOutperformNovavaxOutperform Votes84974.08% Underperform Votes29725.92% enGeneOutperform Votes11100.00% Underperform VotesNo Votes SummaryenGene beats Novavax on 8 of the 15 factors compared between the two stocks. Ad Weiss RatingsTrump won. Buy this coin now.Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will go to $150,000 — or more. But there’s one coin he thinks could go even higher.This could be his favorite coin. Get enGene News Delivered to You Automatically Sign up to receive the latest news and ratings for ENGN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ENGN vs. The Competition Export to ExcelMetricenGeneBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$337.36M$2.88B$5.01B$8.72BDividend YieldN/A1.89%7.62%4.07%P/E RatioN/A14.1982.7813.06Price / SalesN/A286.241,392.0188.46Price / Cash1.69160.0933.0332.45Price / Book2.463.564.604.60Net Income-$99.92M-$42.51M$117.53M$225.14M7 Day Performance-10.09%-11.36%-3.16%-1.82%1 Month Performance-15.08%-8.02%-4.58%-0.78%1 Year Performance0.13%22.42%29.14%23.20% enGene Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ENGNenGene3.1128 of 5 stars$7.95+3.8%$31.43+295.3%+0.1%$351.55MN/A0.0031Analyst ForecastGap UpNVAXNovavax3.7093 of 5 stars$7.83+7.0%N/A+36.6%$1.17B$983.71M-3.461,543Earnings ReportAnalyst RevisionMESOMesoblast0.8914 of 5 stars$10.64+6.0%N/A+350.6%$1.15B$5.90M0.0080Gap UpVIRVir Biotechnology3.2579 of 5 stars$7.03-12.2%N/A-27.5%$1.10B$86.18M-1.79587IMTXImmatics2.1202 of 5 stars$7.82-4.3%N/A-9.9%$933.36M$70.87M-8.79260News CoverageGap UpHigh Trading VolumeLENZLENZ Therapeutics0.6809 of 5 stars$32.92-0.8%N/AN/A$913.03MN/A0.00N/APositive NewsRLAYRelay Therapeutics3.4479 of 5 stars$4.89-4.3%N/A-43.3%$854.49M$25.55M-1.87304AUTLAutolus Therapeutics3.5022 of 5 stars$2.99-2.9%N/A-32.8%$819.57M$1.70M-2.47330Earnings ReportAnalyst UpgradeNews CoverageCGEMCullinan Therapeutics1.7319 of 5 stars$13.45-3.0%N/A+52.8%$807.03M$18.94M-4.7430Positive NewsADPTAdaptive Biotechnologies4.3114 of 5 stars$4.68-7.9%N/A+8.6%$749.70M$170.28M-3.49709Short Interest ↓Analyst RevisionGap DownREPLReplimune Group4.0693 of 5 stars$10.77-0.3%N/A+3.6%$738.91MN/A-3.53210Earnings ReportHigh Trading Volume Related Companies and Tools Related Companies NVAX Competitors MESO Competitors VIR Competitors IMTX Competitors LENZ Competitors RLAY Competitors AUTL Competitors CGEM Competitors ADPT Competitors REPL Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ENGN) was last updated on 11/19/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding enGene Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share enGene With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
